MUMBAI (Reuters) - Sun Pharmaceutical Industries Ltd , India's top drugmaker by market value, reported a net loss of 12.76 billion rupees for the June quarter, due to a provision for settling a patent suit, it said on Friday.
The Mumbai-based company said net sales rose 31 percent to 34.82 billion rupees for the first quarter ended June 30.
Sun Pharma, along with Teva Pharmaceuticals Industries Ltd , has to pay Pfizer Inc $2.15 billion to settle a patent suit related to marketing generic versions of its acid-reflux drug Protonix.
(Reporting by Prashant Mehra; Editing by Prateek Chatterjee)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app